Acerta Pharma B.V. et al v. Natco Pharma Limited et al
| Acerta Pharma B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Merck Sharp & Dohme B.V. |
| Natco Pharma Limited and Natco Pharma, Inc. |
| 1:2022cv00155 |
| February 2, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 2, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Pro Hac Vice Attorney Kevin Hoagland-Hanson, Min Kyung Jeon, Stanley E. Fisher, David I. Berl, and Sarahi Uribe for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V., added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(smg) |
SO ORDERED, re #12 STIPULATION and Proposed Order for Extension of to Response to the Complaint (*Reset Answer Deadlines: Natco Pharma Limited answer due 4/11/2022; Natco Pharma, Inc. answer due 4/11/2022). Signed by Judge Richard G. Andrews on 2/23/2022. (nms)
|
| Filing 12 STIPULATION and Proposed Order for Extension of to Response to the Complaint - filed by Natco Pharma Limited, Natco Pharma, Inc.. (Green, James) Modified on 2/23/2022 (nms). |
| Filing 11 MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon - filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Certifications for David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon)(Joyce, Alexandra) |
|
SO ORDERED, re (12 in 22-cv-164-RGA; 11 in 22-cv-155-RGA; 11 in 22-cv-162-RGA; 11 in 22-cv-163-RGA; 11 in 22-cv-154-RGA) MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon, filed by Merck Sharp & Dohme B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, Acerta Pharma B.V.. Signed by Judge Richard G. Andrews on 2/17/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA (rjb) |
| Filing 10 SUMMONS Returned Executed by AstraZeneca AB, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. Natco Pharma, Inc. served on 2/3/2022, answer due 2/24/2022. (Joyce, Alexandra) |
| Filing 9 DECLARATION of Service of Natco Pharma Limited, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Exhibits A-B)(Joyce, Alexandra) Modified on 2/9/2022 (nms). |
| Filing 8 Summons Issued with Magistrate Consent Notice attached as to Natco Pharma Limited on 2/2/2022; Natco Pharma, Inc. on 2/2/2022. (Attachments: #1 Summons Issued)(mal) |
| Filing 7 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited. (mal) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme B.V. filed by Merck Sharp & Dohme B.V.. (mal) |
| Filing 5 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,272,083. (mal) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,290,504 ;9,758,524 ;10,239,883 ;9,796,721 ;10,167,291. (mal) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than 12/20/2021. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: No earlier than 4/30/2025. (mal) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Filing 1 COMPLAINT filed against Natco Pharma Limited, Natco Pharma, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3794357.) - filed by AstraZeneca AB, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Exhibit A-F, #2 Civil Cover Sheet)(mal) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
